Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.

Published

Journal Article

BACKGROUND: A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased donor was received. The generalizability of that finding is unclear. METHODS: In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who were matched with controls who remained on the waiting list or received a transplant from a deceased donor (waiting-list-or-transplant control group) and controls who remained on the waiting list but did not receive a transplant (waiting-list-only control group). We analyzed the data with and without patients from the highest-volume center in the study. RESULTS: Recipients of kidney transplants from incompatible live donors had a higher survival rate than either control group at 1 year (95.0%, vs. 94.0% for the waiting-list-or-transplant control group and 89.6% for the waiting-list-only control group), 3 years (91.7% vs. 83.6% and 72.7%, respectively), 5 years (86.0% vs. 74.4% and 59.2%), and 8 years (76.5% vs. 62.9% and 43.9%) (P<0.001 for all comparisons with the two control groups). The survival benefit was significant at 8 years across all levels of donor-specific antibody: 89.2% for recipients of kidney transplants from incompatible live donors who had a positive Luminex assay for anti-HLA antibody but a negative flow-cytometric cross-match versus 65.0% for the waiting-list-or-transplant control group and 47.1% for the waiting-list-only control group; 76.3% for recipients with a positive flow-cytometric cross-match but a negative cytotoxic cross-match versus 63.3% and 43.0% in the two control groups, respectively; and 71.0% for recipients with a positive cytotoxic cross-match versus 61.5% and 43.7%, respectively. The findings did not change when patients from the highest-volume center were excluded. CONCLUSIONS: This multicenter study validated single-center evidence that patients who received kidney transplants from HLA-incompatible live donors had a substantial survival benefit as compared with patients who did not undergo transplantation and those who waited for transplants from deceased donors. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.).

Full Text

Duke Authors

Cited Authors

  • Orandi, BJ; Luo, X; Massie, AB; Garonzik-Wang, JM; Lonze, BE; Ahmed, R; Van Arendonk, KJ; Stegall, MD; Jordan, SC; Oberholzer, J; Dunn, TB; Ratner, LE; Kapur, S; Pelletier, RP; Roberts, JP; Melcher, ML; Singh, P; Sudan, DL; Posner, MP; El-Amm, JM; Shapiro, R; Cooper, M; Lipkowitz, GS; Rees, MA; Marsh, CL; Sankari, BR; Gerber, DA; Nelson, PW; Wellen, J; Bozorgzadeh, A; Gaber, AO; Montgomery, RA; Segev, DL

Published Date

  • March 10, 2016

Published In

Volume / Issue

  • 374 / 10

Start / End Page

  • 940 - 950

PubMed ID

  • 26962729

Pubmed Central ID

  • 26962729

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1508380

Language

  • eng

Conference Location

  • United States